
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a promising epigenetics company with a robust platform in Nucleosomics and a range of life-altering disease tests in development. The potential for additional licensing deals and the company's successful clinical certification and inclusion in an early detection evaluation bode well for future revenue growth. While there are some potential risks, such as the reverse stock split and potential dilution, the overall outlook for VolitionRX appears positive at this time and the stock is currently rated as a Buy with a 12-month price target of $1.
Bears say
VolitionRX is currently facing major financial challenges, including low cash reserves and ongoing negative cash flows. While the company has recently announced promising proof of concept data for their liquid biopsy method, it will still require further validation and regulatory approval before it can generate significant revenue. As such, there remains significant uncertainty and risk surrounding the company's ability to successfully commercialize its technology and achieve financial success.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares